<DOC>
	<DOCNO>NCT01645800</DOCNO>
	<brief_summary>The aim study ass effectiveness prevent exacerbation 52 week lysozyme administration patient COPD .</brief_summary>
	<brief_title>Effects Lysozyme Acute Exacerbation Chronic Obstructive Pulmonary Disease : A Randomised Placebo-Controlled Study</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Muramidase</mesh_term>
	<criteria>Inclusion criterion ; Patients eligible inclusion study 20 year age 85 year age , smoke history , diagnosis COPD , ratio FEV1 force vital capacity ( FVC ) less 70 % , documented history least one exacerbation lead treatment within previous year . Exclusion criterion ; Patients egg allergy Patients domiciliary oxygen therapy Patients pneumonia pulmonary tuberculosis Patients severe cardiovascular disorder , severe kidney disorder , severe hepatic disorder , severe hematological disorder . Patients cancer .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Lysozyme hydrochloride</keyword>
	<keyword>COPD</keyword>
</DOC>